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Introduction: Congenital left coronary ostial atresia or severe stenosis is
an extremely rare coronary abnormality. The clinical picture is either cardiac
failure in the small infant or chest pain in the older child or adult patient. This
report describes four neonatal cases of this rare abnormality.
Methods: We retrospectively accessed all cases of left coronary ostial ste-
nosis or atresia seen in our center during an 11-year-period (2000 – 2011).
Two older patients with this diagnosis seen at 18 months and 4 years were
excluded from the study.
Results: Four neonates with the diagnosis of left coronary ostial atresia or
stenosis were identified during the study period. One newborn died within
minutes, the other within hours after birth because of cardiac failure refractory
to all treatment strategies. In both cases left coronary stenosis (one case with
a “pinpoint” orifice and the other with a “slitlike” orifice) was diagnosed at
autopsy. The third neonate was in cardiac failure due to a severe aortic ste-
nosis. Left coronary ostial atresia was diagnosed during emergency catheter
procedure. The infant subsequently died after the aortic dilatation. The forth
infant had a cardiac arrest at the third day of life after normal delivery and
neonatal adaptation. She was diagnosed with left coronary ostium atresia by
coronary angiography performed because of persistent biventricular dysfunc-
tion. She died during the attempt of revascularization surgery at 2 weeks of
life.
Conclusion: Congenital left coronary ostium atresia or stenosis is very
rare. Coronary angiography is the diagnostic method of choice especially in
the small child or infant. Revascularization surgery seems indicated in symp-
tomatic children based on case reports and smalls series. The clinical picture
described here for the first time in the neonate is dramatic and quickly fatal
with scarce surgical options. Systematic examination of the coronaries should
be part of any neonatal autopsy.
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The transcatheter closure of Atrial Septal Defect (ASD) in patients
older than 60 years : Retrospective study of 41 cases
Aimé Bama, Claire Dauphin, Jean Paul Chadefaux, Jean René Lusson
CHU Gabriel Montpied, cardiologie A, Clermont Ferrand, France
Introduction: Transcatheter closure of ASD is now proposed as first line
treatment for the elderly patients.
Purpose: The aim of our study is to evaluating the transcatheter closure of
ASD in patients older than 60 years.
Methods:The records of 41 patients (37 women, 4 men) who are over 60
years (69.88±6 years, range 61-82 years), referred between April 1998 and
December 2010 for transcatheter closure of secundum ASD, were retrospec-
tively reviewed
Results: ASD was discovered during the assessment of patients with dys-
pnea (17) or arrhythmia (17). Average age at time of diagnosis was
62.4±14.89 years (range 14-82 years). 37.8% of cases had a delayed diagnosis.
At time of the procedure, 19 patients (46.3%) had supraventricular
arrhythmia and 82.9% of patients were dyspneic. Shunt ratio was 2.50±0.66,
defect size 19.67±6.76 mm, stretched diameter 24.36 mm±5.87, device dia-
meter of 24.49 mm±6.58. One patient was recused, because of increased left
atrial pressure at occlusion test.
Fluoroscopy time was 7.01±4.41 min.Success rate is 97.5%. Complete clo-
sure rate at one day and one month was 84.6% and 94.9% respectively. Sys-
tolic pulmonary pressure decreased from 49.37 to 34,58 mmHg at one month.
Hospital stay was 3.58 days ± 2.71.Periprocedural complication rate was
12.2%. 2 complications were major: one death by esophageal hematoma, and
one oropharyngeal bleeding, and 3 minors: 3 femoral arteriovenous fistulas.
At late follow-up (34±44 months, range 1month to 12 years), 34 patients
were in stage one, 4 recurred supraventricular arrhythmia, 1 needed pace
maker for sinus node dysfunction.
Conclusion: Transcatheter closure of ASD in ederly patients is effective.
It does not change rhythmic status but allows symptomatic improvement.
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Background: Pulmonary vasodilators in general and prostacyclin therapy
in particular have markedly improved the outcome of patients with pulmonary
arterial hypertension (PAH). Endothelial dysfunction is a key feature of PAH
and we previously described that circulating endothelial cells (CECs) could be
used as a biomarker of endothelial dysfunction in PAH. We now hypothesized
that PAH-specific vasodilator therapy might decrease CEC numbers.
Methods: We quantified CECs in peripheral blood from children with idio-
pathic PAH (iPAH, n =30) or PAH secondary to congenital heart disease (PAH-
CHD, n =30), before and after treatment and during follow up. CEC were enu-
merated by immunomagnetic separation with mAb CD146-coated beads.
Results: CEC counts were significantly decreased in children after treat-
ment with oral endothelin antagonists and/or PDE5 inhibitors. In 10 children
with refractory PAH despite combination oral therapies, SC treprostinil was
added and we found a further significant decrease in CEC count during the
first month of treatment in every patient. We quantified CEC during 6 to
36 months follow-up after initiation of SC treprostinil and found that CEC
count is modified according to clinical status.
Conclusions: CEC counts fall with vasodilatator therapy in PAH and could
also be used as biomarker of deterioration in refractory pediatric pulmonary
hypertension treated with SC treprostinil.
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Use of covered stents for closure of fenestration in extracardiac
cavopulmonary connection: technical aspects and mid-term results
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Objective: Closure of fenestration in a cavopulmonary connection (TCPC)
is performed with devices used to close intracardiac or aorto-pulmonary
connections. This study presents our data regarding the use of covered stents
in patients with fenestrated TCPC.
Methods: We retrospectively reviewed the data of all the patients receiving
a covered stent to close a fenestration of TCPC between 2005 and 2012.
Results: 38 patients were included. Mean age and weight were respectively
7.6 years and 20 kg. Femoral access was mainly used (32) but also jugular
access (5) and trans-hepatic access (1). A Cheatham Platinum Stent was used
(34) but we also used Atrium V12 Stents (4). The balloon size was chosen
according to the diameter of the conduit. We used BIB balloon (14) or simple
balloon (Tyshak or Balt) (16) (balloon not reported (4)). Mean procedural and
fluoroscopy times were respectively 42,5 +/ – 21 and 7,5±6,6 minutes. Mean
central venous pressure rose from 10 to 12mmHg. Mean oxygen saturation
increased from 90% to 96%. There was one anaphylactic shock at the end of the
procedure and one air embolisation without hemodynamic compromise. Full
occlusion was confirmed on angiogram in 36 patients. 2 cases required 2 stents
to achieve full occlusion. There was one minimal residual shunt and one failure
of the procedure with significant residual shunt in a patient with a conduit made
of a Gore-Tex patch between the atrium and the pulmonary arteries. There were
no embolic event, acute venous thrombosis or arrhythmias. Patients were treated
with anti vitamin K for 6 months then aspirin. Mean follow-up is 49 months
without thrombo-embolic complication or desaturation.
Conclusion: Covered stent is an option to close fenestration in extracardiac
TCPC. It is safe, easily achievable with low fluoroscopy time, very low risk
of thrombo-embolic events or failure. The good results are sustainable. The
main advantage of the technique is to avoid prosthetic device in the atrium
